Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability

Lorraine G. Shapeero, Daniel Vanel, Koenraad L. Verstraete, Johan L. Bloem

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Because dynamic (fast) contrast-enhanced magnetic resonance imaging with its temporal resolution allows evaluation of contrast kinetics of soft tissue sarcomas, its efficacy for defining viable tumor in these neoplasms was studied for three applications: biopsy localization, chemotherapeutic response, and differentiation between recurrence and inflammation after treatment. After conventional T1-weighted and T2-weighted magnetic resonance sequences to localize the lesion, patients had dynamic contrast-enhanced magnetic resonance imaging with fast and ultrafast sequences and postprocessing techniques (subtraction, time-intensity curves, and parametric color-encoding). In 10 of 40 patients, dynamic imaging more precisely defined the most malignant foci of tumor for biopsy than conventional magnetic resonance imaging. After chemotherapy, dynamic imaging distinguished 11 good responders from 21 poor responders. In followup of 196 patients, dynamic imaging detected 42 early enhancing recurrences and excluded recurrent tumor in six late enhancing pseudotumors. Dynamic imaging can differentiate viable tumor from nonviable tumor and inflammation by showing two temporally different phases of contrast enhancement: an early phase correlative with viable tumor at histologic examination, and a late phase when all tissues enhance simultaneously and may be indistinguishable. By showing tumor viability, dynamic contrast-enhanced magnetic resonance imaging can help define biopsy sites, chemotherapeutic response, and presence or absence of recurrences and therefore affect the initial evaluation, treatment, and followup of patients with soft tissue sarcomas.

Original languageEnglish
Pages (from-to)212-227
Number of pages16
JournalClinical Orthopaedics and Related Research
Issue number397
Publication statusPublished - 2002

Fingerprint

Tissue Survival
Sarcoma
Magnetic Resonance Imaging
Neoplasms
Biopsy
Recurrence
Subtraction Technique
Inflammation
Magnetic Resonance Spectroscopy
Color
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Shapeero, L. G., Vanel, D., Verstraete, K. L., & Bloem, J. L. (2002). Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clinical Orthopaedics and Related Research, (397), 212-227.

Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. / Shapeero, Lorraine G.; Vanel, Daniel; Verstraete, Koenraad L.; Bloem, Johan L.

In: Clinical Orthopaedics and Related Research, No. 397, 2002, p. 212-227.

Research output: Contribution to journalArticle

Shapeero, LG, Vanel, D, Verstraete, KL & Bloem, JL 2002, 'Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability', Clinical Orthopaedics and Related Research, no. 397, pp. 212-227.
Shapeero, Lorraine G. ; Vanel, Daniel ; Verstraete, Koenraad L. ; Bloem, Johan L. / Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. In: Clinical Orthopaedics and Related Research. 2002 ; No. 397. pp. 212-227.
@article{9be6fcb2582740338f90482e30603708,
title = "Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability",
abstract = "Because dynamic (fast) contrast-enhanced magnetic resonance imaging with its temporal resolution allows evaluation of contrast kinetics of soft tissue sarcomas, its efficacy for defining viable tumor in these neoplasms was studied for three applications: biopsy localization, chemotherapeutic response, and differentiation between recurrence and inflammation after treatment. After conventional T1-weighted and T2-weighted magnetic resonance sequences to localize the lesion, patients had dynamic contrast-enhanced magnetic resonance imaging with fast and ultrafast sequences and postprocessing techniques (subtraction, time-intensity curves, and parametric color-encoding). In 10 of 40 patients, dynamic imaging more precisely defined the most malignant foci of tumor for biopsy than conventional magnetic resonance imaging. After chemotherapy, dynamic imaging distinguished 11 good responders from 21 poor responders. In followup of 196 patients, dynamic imaging detected 42 early enhancing recurrences and excluded recurrent tumor in six late enhancing pseudotumors. Dynamic imaging can differentiate viable tumor from nonviable tumor and inflammation by showing two temporally different phases of contrast enhancement: an early phase correlative with viable tumor at histologic examination, and a late phase when all tissues enhance simultaneously and may be indistinguishable. By showing tumor viability, dynamic contrast-enhanced magnetic resonance imaging can help define biopsy sites, chemotherapeutic response, and presence or absence of recurrences and therefore affect the initial evaluation, treatment, and followup of patients with soft tissue sarcomas.",
author = "Shapeero, {Lorraine G.} and Daniel Vanel and Verstraete, {Koenraad L.} and Bloem, {Johan L.}",
year = "2002",
language = "English",
pages = "212--227",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "397",

}

TY - JOUR

T1 - Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability

AU - Shapeero, Lorraine G.

AU - Vanel, Daniel

AU - Verstraete, Koenraad L.

AU - Bloem, Johan L.

PY - 2002

Y1 - 2002

N2 - Because dynamic (fast) contrast-enhanced magnetic resonance imaging with its temporal resolution allows evaluation of contrast kinetics of soft tissue sarcomas, its efficacy for defining viable tumor in these neoplasms was studied for three applications: biopsy localization, chemotherapeutic response, and differentiation between recurrence and inflammation after treatment. After conventional T1-weighted and T2-weighted magnetic resonance sequences to localize the lesion, patients had dynamic contrast-enhanced magnetic resonance imaging with fast and ultrafast sequences and postprocessing techniques (subtraction, time-intensity curves, and parametric color-encoding). In 10 of 40 patients, dynamic imaging more precisely defined the most malignant foci of tumor for biopsy than conventional magnetic resonance imaging. After chemotherapy, dynamic imaging distinguished 11 good responders from 21 poor responders. In followup of 196 patients, dynamic imaging detected 42 early enhancing recurrences and excluded recurrent tumor in six late enhancing pseudotumors. Dynamic imaging can differentiate viable tumor from nonviable tumor and inflammation by showing two temporally different phases of contrast enhancement: an early phase correlative with viable tumor at histologic examination, and a late phase when all tissues enhance simultaneously and may be indistinguishable. By showing tumor viability, dynamic contrast-enhanced magnetic resonance imaging can help define biopsy sites, chemotherapeutic response, and presence or absence of recurrences and therefore affect the initial evaluation, treatment, and followup of patients with soft tissue sarcomas.

AB - Because dynamic (fast) contrast-enhanced magnetic resonance imaging with its temporal resolution allows evaluation of contrast kinetics of soft tissue sarcomas, its efficacy for defining viable tumor in these neoplasms was studied for three applications: biopsy localization, chemotherapeutic response, and differentiation between recurrence and inflammation after treatment. After conventional T1-weighted and T2-weighted magnetic resonance sequences to localize the lesion, patients had dynamic contrast-enhanced magnetic resonance imaging with fast and ultrafast sequences and postprocessing techniques (subtraction, time-intensity curves, and parametric color-encoding). In 10 of 40 patients, dynamic imaging more precisely defined the most malignant foci of tumor for biopsy than conventional magnetic resonance imaging. After chemotherapy, dynamic imaging distinguished 11 good responders from 21 poor responders. In followup of 196 patients, dynamic imaging detected 42 early enhancing recurrences and excluded recurrent tumor in six late enhancing pseudotumors. Dynamic imaging can differentiate viable tumor from nonviable tumor and inflammation by showing two temporally different phases of contrast enhancement: an early phase correlative with viable tumor at histologic examination, and a late phase when all tissues enhance simultaneously and may be indistinguishable. By showing tumor viability, dynamic contrast-enhanced magnetic resonance imaging can help define biopsy sites, chemotherapeutic response, and presence or absence of recurrences and therefore affect the initial evaluation, treatment, and followup of patients with soft tissue sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=0036237126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036237126&partnerID=8YFLogxK

M3 - Article

C2 - 11953613

AN - SCOPUS:0036237126

SP - 212

EP - 227

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 397

ER -